Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence

  • Yun, Do-Kyung (Department of Biochemistry, College of Pharmacy, Dongguk University) ;
  • Lee, June (Department of Chemistry, Dongguk University) ;
  • Keum, Young-Sam (Department of Biochemistry, College of Pharmacy, Dongguk University)
  • Received : 2012.10.15
  • Accepted : 2012.12.11
  • Published : 2013.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

A number of naturally-occurring or synthetic chemicals have been reported to exhibit prostate chemopreventive effects. Synthetic $5{\alpha}$-reductase (5-AR) inhibitors, e.g. finasteride and durasteride, gained special interests as possible prostate chemopreventive agents. Indeed, two large-scale epidemiological studies have demonstrated that finasteride or durasteride significantly reduced the incidence of prostate cancer formation in men. However, these studies have raised an unexpected concern; finasteride and durasteride increased the occurrence of aggressive prostate tumor formation. In the present study, we have observed that treatment of finasteride did not affect the growth of androgen-refractory PC-3 prostate cancer cells. Finasteride also failed to induce apoptosis or affect the expression of proto-oncogenes in PC-3 cells. Interestingly, we found that treatment of finasteride induced the expression of Nrf2 and HO-1 proteins in PC-3 cells. In particular, basal level of Nrf2 protein was higher in androgen-refractory prostate cancer cells, e.g. DU-145 and PC-3 cells, compared with androgen-responsive prostate cancer cells, e.g. LNCaP cells. Also, treatment of finasteride resulted in a selective induction of Nrf2 protein in DU-145 and PC-3 cells, but not in LNCaP cells. In view of the fact that upregulation of Nrf2-mediated phase II cytoprotective enzymes contribute to attenuating tumor promotion in normal cells, but, on the other hand, confers a selective advantage for cancer cells to proliferate and survive against chemical carcinogenesis and other forms of toxicity, we propose that finasteride-mediated induction of Nrf2 protein might be responsible, at least in part, for an increased risk of high-grade prostate tumor formation in men.

Keywords

References

  1. Aalinkeel, R., Nair, M. P., Sufrin, G., Mahajan, S. D., Chadha, K. C., Chawda, R. P. and Schwartz, S. A. (2004) Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res. 64, 5311-5321. https://doi.org/10.1158/0008-5472.CAN-2506-2
  2. Aggarwal, S., Thareja, S., Verma, A., Bhardwaj, T. R. and Kumar, M. (2010) An overview on 5alpha-reductase inhibitors. Steroids 75, 109-153. https://doi.org/10.1016/j.steroids.2009.10.005
  3. Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., Somerville, M. C., Wilson, T. H., Fowler, I. L. and Rittmaster, R. S. (2010) Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192-1202. https://doi.org/10.1056/NEJMoa0908127
  4. Azzouni, F. and Mohler, J. (2012) Role of 5a-reductase inhibitors in prostate cancer prevention and treatment. Urology 79, 1197-1205. https://doi.org/10.1016/j.urology.2012.01.024
  5. Bostwick, D. G., Qian, J., Civantos, F., Roehrborn, C. G. and Montironi, R. (2004) Does finasteride alter the pathology of the prostate and cancer grading? Clin. Prostate Cancer 2, 228-235. https://doi.org/10.3816/CGC.2004.n.004
  6. Gooren, L. (2005) Hormone treatment of the adult transsexual patient. Horm. Res. 64 Suppl 2, 31-36. https://doi.org/10.1159/000087751
  7. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S. and et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 327, 1185-1191. https://doi.org/10.1056/NEJM199210223271701
  8. Kensler, T. W. and Wakabayashi, N. (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31, 90-99. https://doi.org/10.1093/carcin/bgp231
  9. Keum, Y. S. (2011) Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann N Y Acad Sci 1229, 184-189. https://doi.org/10.1111/j.1749-6632.2011.06092.x
  10. Keum, Y. S., Jeong, W. S. and Kong, A. N. (2004) Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat. Res. 555, 191-202. https://doi.org/10.1016/j.mrfmmm.2004.05.024
  11. Lippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S., Thompson, I. M., Ford, L. G., Parnes, H. L., Minasian, L. M., Gaziano, J. M., Hartline, J. A., Parsons, J. K., Bearden, J. D. 3rd, Crawford, E. D., Goodman, G. E., Claudio, J., Winquist, E., Cook, E. D., Karp, D. D., Walther, P., Lieber, M. M., Kristal, A. R., Darke, A. K., Arnold, K. B., Ganz, P. A., Santella, R. M., Albanes, D., Taylor, P. R., Probstfield, J. L., Jagpal, T. J., Crowley, J. J., Meyskens, F. L. Jr., Baker, L. H. and Coltman, C. A. Jr. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51.
  12. Nacusi, L. P. and Tindall, D. J. (2011) Targeting 5a-reductase for prostate cancer prevention and treatment. Nat. Rev. Urol. 8, 378-384. https://doi.org/10.1038/nrurol.2011.67
  13. Paine, A., Eiz-Vesper, B., Blasczyk, R. and Immenschuh, S. (2010) Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem. Pharmacol. 80, 1895-1903. https://doi.org/10.1016/j.bcp.2010.07.014
  14. Riedl, S. J. and Shi, Y. (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 5, 897-907. https://doi.org/10.1038/nrm1496
  15. Rittmaster, R. S. (1997) 5alpha-reductase inhibitors. J. Androl. 18, 582-587.
  16. Surh, Y. J. (2003) Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3, 768-780. https://doi.org/10.1038/nrc1189
  17. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J. and Coltman, C. A. Jr. (2003) The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224. https://doi.org/10.1056/NEJMoa030660
  18. Tong, K. I., Kobayashi, A., Katsuoka, F. and Yamamoto, M. (2006) Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol. Chem. 387, 1311-1320.
  19. Walsh, P. C. (2010) Chemoprevention of prostate cancer. N. Engl. J. Med. 362, 1237-1238. https://doi.org/10.1056/NEJMe1001045

Cited by

  1. Gagamyeonryunggobon-dan(Jiājiǎnyánlínggùběn-dān) induces hair regrowth effect from activating hair follicle vol.29, pp.1, 2016, https://doi.org/10.6114/jkood.2016.29.1.065
  2. The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression vol.55, pp.6, 2014, https://doi.org/10.4111/kju.2014.55.6.367
  3. Finasteride promotes worsening of the cardiac deleterious effects of nandrolone decanoate and protects against genotoxic and cytotoxic damage vol.56, pp.None, 2013, https://doi.org/10.1590/s2175-97902019000318289